PHILADELPHIA – Around the home, regularly used tools are generally kept close at hand: a can opener in a kitchen drawer, a broom in the hall closet. Less frequently used tools are more likely to be stored in less accessible locations, out of immediate reach, perhaps in the basement or garage. And hazardous tools might even be kept under lock and key.
Similarly, the human genome has developed a set of sophisticated mechanisms for keeping selected genes readily available for use while other genes are kept securely stored away for long periods of time, sometimes forever. Candidate genes for such long-term storage include those required only for early development and proliferation, potentially dangerous genes that could well trigger cancers and other disorders should they be reactivated later in life. Cancer researchers and others have been eager to learn more about the molecules that direct this all-important system for managing the genome.
Now, researchers at The Wistar Institute and Fox Chase Cancer Center have successfully determined the three-dimensional structure of a key two-molecule complex involved in long-term gene storage, primarily in cells that have ceased proliferating, or growing. The study also sheds light on a related two-molecule complex that incorporates one member of the molecular pair, but with a different partner. This second complex is involved in storing genes in a more accessible way in cells that continue to grow. A report on the team's findings, published online on September 17, will appear in the October issue of Nature Structural and Molecular Biology.
"The two-molecule complex we studied is pivotal for protecting certain genes from expression, genes that could cause problems if they were activated," says Ronen Marmorstein, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and one of the two senior authors on the study. "This is the first time we've been able to see the structure of these molecules communicating and interacting with each other, and it provides important insights into their function."
"By defining some of the rules that dictate how these complexes are formed and operate, we have revealed a part of the difference between growing and non-growing cells," says Peter D. Adams, Ph.D., an associate member in the Basic Science Division at Fox Chase and the other senior author on the study. "This difference is crucial to the distinction between normal and cancerous cells and may inform our ability to treat this disease."
The molecular complex studied by the scientists governs the assembly of an especially condensed form of chromatin, the substructure of chromosomes. The complex is called a histone chaperone complex, responsible for inserting the appropriate histones into the correct locations within the chromatin. Histones are relatively small proteins around which DNA is coiled to create structures called nucleosomes. Compact strings of nucleosomes, then, form into chromatin.
"There are more and less condensed forms of chromatin," explains Marmorstein. "The less condensed forms correlate with more gene expression, and the more condensed forms involve DNA that's buried away and is not transcribed."
"Appropriate packaging of the DNA in the cell nucleus is crucial for proper functioning of the cell and suppression of disease states, such as cancer," says Adams.
An unanticipated observation from the study centers on the region of association between the two molecules in the complex. The researchers knew that one of the two molecules in the complex, called ASF1, associated with a particular molecular partner, HIRA, when directing assembly of the more condensed form of chromatin. But it could also associate with a different partner, called CAF1, to shepherd assembly of the less condensed form of chromatin.
On closer study, the scientists discovered that HIRA and CAF1 have nearly identical structural motifs in the regions of interaction with ASF1. This means that ASF1 can bind to one or the other molecular partner, but not to both. In other words, the interaction is mutually exclusive: A kind of decision is made by ASF1 as to whether to guide the assembly process towards the more or less condensed forms of chromatin. What determines the choice? The relevant factors are unknown for now.
The two lead authors on the study are Yong Tang at Wistar and Maxim V. Poustovoitov at Fox Chase. Kehao Zhao at Wistar is a coauthor, as are Megan Garfinkel, Adrian Canutescu, and Roland Dunbrack at Fox Chase.
Funding for the research was provided by the National Institutes of Health, the Leukemia and Lymphoma Society, and the Commonwealth Universal Research Enhancement Program of the Pennsylvania Department of Health.
The Wistar Institute is an international leader in biomedical research, with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. Discoveries at Wistar have led to the creation of the rubella vaccine that eradicated the disease in the U.S., rabies vaccines used worldwide, and a new rotavirus vaccine approved in 2006. Wistar scientists have also identified many cancer genes and developed monoclonal antibodies and other important research tools. Today, Wistar is home to eminent melanoma researchers and pioneering scientists working on experimental vaccines against flu, HIV, and other diseases. The Institute works actively to transfer its inventions to the commercial sector to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today's Discoveries – Tomorrow's Cures. On the web at www.wistar.org.
Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.